Last update 23 Jan 2025

Immunovant Sciences Ltd.

Subsidiary Company|
Bermuda

Overview

Tags

Skin and Musculoskeletal Diseases
Eye Diseases
Neoplasms
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease2
Neoplasms2
Nervous System Diseases2
Immune System Diseases2
Hemic and Lymphatic Diseases1
Infectious Diseases1
Top 5 Drug TypeCount
Monoclonal antibody2
Top 5 TargetCount
FcRn(IgG receptor FcRn large subunit p51)2

Related

2
Drugs associated with Immunovant Sciences Ltd.
Batoclimab
Target
FcRn
Mechanism
FcRn antagonists [+1]
Active Org.
Immunovant Sciences Ltd. [+10]
Originator Org.
HANALL BIOPHARMA Co., Ltd.HANALL BIOPHARMA Co., Ltd.
Active Indication
Myasthenia Gravis [+7]
Inactive Indication
Autoimmune Haemolytic Anaemias
Drug Highest PhaseNDA/BLA
First Approval Ctry. / Loc.-
First Approval Date-
IMVT-1402
Target
FcRn
Mechanism
FcRn antagonists
Active Org.
Immunovant, Inc.Immunovant, Inc. [+2]
Originator Org.
Immunovant, Inc.Immunovant, Inc.
Active Indication
Graves Disease [+4]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
17
Clinical Trials associated with Immunovant Sciences Ltd.
NCT06727604
/ RecruitingPhase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
NCT06754462
/ Not yet recruitingPhase 2
A Phase 2b, Multicenter, Double-blind, Placebo-controlled Randomized Withdrawal Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat, ACPA-Positive Rheumatoid Arthritis
ISRCTN11659633
/ RecruitingPhase 1
A phase I, randomized, double-blind, placebo-controlled, ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMVT-1402 following single and multiple doses in healthy participants and open-label cohorts in participants with autoimmune diseases
100 Clinical Results associated with Immunovant Sciences Ltd.
Login to view more data
0 Patents (Medical) associated with Immunovant Sciences Ltd.
Login to view more data
100 Deals associated with Immunovant Sciences Ltd.
Login to view more data
100 Translational Medicine associated with Immunovant Sciences Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
1
Phase 3 Clinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Batoclimab
 ( FcRn )		Myasthenia Gravis
More
Phase 3
IMVT-1402
 ( FcRn )		Graves Disease
More
Phase 2
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free